CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
Cangrelor +2 moredrug
Likely dose
Cangrelor 30 microgramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01979445
NCT01979445Phase 2Completed
CompareCT.gov

A Study of the Transition From Cangrelor to Clopidogrel or Prasugrel in Patients With Coronary Artery Disease.

The Medicines Company·interventional·Posted Nov 8, 2013·Updated Feb 26, 2020

In Brief

A Phase 2 clinical trial evaluating Cangrelor, Clopidogrel, and 1 other intervention for Coronary Artery Disease (CAD). Completed, enrolled 15 participants across 1 site.

Detailed Summary

There are two separate objectives in this study: 1. To demonstrate the pharmacodynamic (PD) profile when participants treated with cangrelor are switched to oral prasugrel 60 mg administered 30 minutes (min) after cangrelor infusion is discontinued 2. To demonstrate the PD profile when participants treated with cangrelor are switched to oral clopidogrel 600 mg administered during or immediately after cangrelor infusion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease (CAD)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 8, 2013
Enrollment StartDec 2, 2013
Primary CompletionJan 20, 2014
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 12.7 years ago

Interventions

Cangrelordrug

Cangrelor intravenously (IV) administered as a 30 microgram (µg)/kilogram (kg) bolus, followed by 4 µg/kg/min infusion for 2 hrs on Day 1.

Clopidogreldrug

Clopidogrel 600 mg single oral dose

Prasugreldrug

Prasugrel 60 mg single oral dose